AgeX Therapeutics, Inc. (AGE)
|Net Income (ttm)||-11.13M|
|Trading Day||January 21|
|Day's Range||1.88 - 1.98|
|52-Week Range||0.68 - 2.56|
AgeX Therapeutics, Inc. Announces That Its Annual Meeting of Stockholders Will Be Conducted Online Only
ALAMEDA, Calif.--(BUSINESS WIRE)--AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE) announced today that due to state and county government health orders, attendance at the AgeX 2020 Annual...
ALAMEDA, Calif.--(BUSINESS WIRE)--AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing innovative regenerative therapeutics to treat human diseases to incre...
AgeX Therapeutics Sublicenses Stem Cell Line ESI-053 to ImStem Biotechnology for Development of Cell Therapy Candidate IMS001 for COVID-19 and Acute Respiratory Distress Syndrome
ALAMEDA, Calif. & FARMINGTON, Conn.--(BUSINESS WIRE)--AgeX Therapeutics, Inc. (“AgeX”: NYSE American: AGE), a biotechnology company developing innovative regenerative therapeutics to treat hum...
AgeX Therapeutics (AGE) stock is soaring higher on Thursday following news of that Juvenescence has a 50% stake in the company. The post AgeX Therapeutics News: Why AGE Stock Is Skyrocketing 1...
AgeX Therapeutics and Lineage Cell Therapeutics Announce Expansion of Agreement Related to ESI Clinical-grade Pluripotent Stem Cell Lines for Therapeutic Purposes
ALAMEDA, Calif. & CARLSBAD, Calif.
AgeX Therapeutics: Revolutionary Potential But Extremely Early
AgeX Therapeutics, a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States. The company's lead cell-based therapeutic candidates in development include AGEX-BAT1, a cell therapy product candidate for the treatment of various age-related metabolic disorders, such as Type II adult-onset diabetes; and AGEX-VASC1, a cell-based therapy to restore vascular support in aged ischemic tissues, such as the ischemic heart. Its lead drug-based therap... [Read more...]
|IPO Date |
Nov 29, 2018
|Stock Exchange |
|Ticker Symbol |
In 2019, AGE's revenue was $1.73 million, an increase of 23.78% compared to the previous year's $1.40 million. Losses were -$12.15 million, 62.0% more than in 2018.